IP Library › Granted Patent US 10,639,292
Granted Patent B2
US 10,639,292 · App. 16/179,896 · Granted May 5, 2020

Method of treating hyperglycemia

Inventors: Jui-Pao Hsu (Taipei, TW); Guang-Tzuu Shane (Taipei, TW); Meng-Ju Lee (Taipei, TW); Yi-Ping Liao (Taipei, TW); Yu-Yin Yeh (Taipei, TW); Shu-Hsien Chang (Taipei, TW)
Assignee: CENTER LABORATORIES, INC.
A61K31/277A61K31/702A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,639,292
App. No.
16/179,896
Granted
May 5, 2020
Kind
B2
Abstract

Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and an α-glycosidase inhibitor in the treatment of conditions and/or disorders related to hyperglycemia.

Claims (8)

1. A method of treating a subject having diabetes mellitus and/or disorders related to diabetes mellitus comprising administering to the subject an effective amount of (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and acarbose, so as to reduce the blood glucose level of the subject.

2. The method of claim 1 , wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is administered to the subject in the amount of 15 to 1,000 mg/day; and the acarbose is administered to the subject in the amount of 10 to 1,000 mg/day.

3. The method of claim 2 , wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is administered to the subject in the amount of 25 to 800 mg/day; and the acarbose is administered to the subject in the amount of 25 to 600 mg/day.

4. The method of claim 1 , wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is administered to the subject in single or divided doses 2 or 3 times each day; while the acarbose is administered to the subject in single or divided doses 2 or 3 times each day.

5. A pharmaceutical composition for the treatment of diabetes mellitus and/or disorders related to diabetes mellitus comprising, (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof, acarbose, and a pharmaceutically acceptable excipient.

6. The pharmaceutical composition of claim 5 , wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition in the amount of 15 to 1,000 mg; and the acarbose is present in the pharmaceutical composition in the amount of 10 to 1,000 mg.

7. The pharmaceutical composition of claim 6 , wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is a is present in the pharmaceutical composition in the amount of 25 to 800 mg; and the acarbose is present in the pharmaceutical composition in the amount of 25 to 600 mg.

8. The pharmaceutical composition of claim 5 , which is administered to the subject in single or divided doses 2 or 3 times each day.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2018
From: HSU, JUI-PAO; SHANE, GUANG-TZUU; LEE, MENG-JU; LIAO, YI-PING; YEH, YU-YIN; CHANG, SHU-HSIEN
To: CENTER LABORATORIES, INC.
Reel/Frame 047567/0767 →
Continuity (2)
Continuation In Part 15957956 · Apr 20, 2018
Related Publication 20190321326A1 · Oct 24, 2019